FY2019 Earnings Forecast for Zoetis Inc (ZTS) Issued By Gabelli

Zoetis Inc (NYSE:ZTS) – Equities research analysts at Gabelli cut their FY2019 earnings per share (EPS) estimates for Zoetis in a report released on Friday, February 15th. Gabelli analyst K. Kedra now forecasts that the company will post earnings of $3.45 per share for the year, down from their prior forecast of $3.50. Gabelli also issued estimates for Zoetis’ FY2021 earnings at $4.40 EPS and FY2023 earnings at $5.30 EPS.

Get Zoetis alerts:

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.02. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the firm posted $0.69 EPS. The firm’s revenue was up 7.1% compared to the same quarter last year.

ZTS has been the subject of a number of other reports. Morgan Stanley set a $100.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a report on Friday, November 2nd. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a report on Saturday. BMO Capital Markets lifted their price objective on shares of Zoetis to $93.00 and gave the stock a “neutral” rating in a report on Monday, November 12th. They noted that the move was a valuation call. UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, November 2nd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $97.08.

NYSE ZTS opened at $95.37 on Monday. Zoetis has a 52-week low of $77.00 and a 52-week high of $96.57. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04. The firm has a market cap of $45.82 billion, a PE ratio of 39.74, a P/E/G ratio of 1.62 and a beta of 0.88.

Zoetis declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, December 12th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.7% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.69%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio is presently 27.50%.

In other Zoetis news, Director Willie M. Reed sold 3,205 shares of the business’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $93.74, for a total value of $300,436.70. Following the transaction, the director now owns 566 shares in the company, valued at $53,056.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $85.30, for a total transaction of $170,600.00. Following the completion of the transaction, the executive vice president now owns 22,023 shares in the company, valued at approximately $1,878,561.90. The disclosure for this sale can be found here. Insiders sold 33,455 shares of company stock valued at $2,958,663 over the last three months. 0.35% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. Glenmede Trust Co. NA increased its position in shares of Zoetis by 40.7% in the third quarter. Glenmede Trust Co. NA now owns 63,355 shares of the company’s stock valued at $5,800,000 after acquiring an additional 18,317 shares during the period. IFM Investors Pty Ltd increased its position in shares of Zoetis by 9.9% in the fourth quarter. IFM Investors Pty Ltd now owns 27,848 shares of the company’s stock valued at $2,382,000 after acquiring an additional 2,516 shares during the period. Baldwin Brothers Inc. MA increased its position in shares of Zoetis by 2.3% in the third quarter. Baldwin Brothers Inc. MA now owns 58,440 shares of the company’s stock valued at $5,351,000 after acquiring an additional 1,300 shares during the period. Bank of Montreal Can increased its position in shares of Zoetis by 1.9% during the fourth quarter. Bank of Montreal Can now owns 1,417,293 shares of the company’s stock valued at $121,234,000 after buying an additional 25,837 shares during the period. Finally, Waldron Private Wealth LLC purchased a new position in shares of Zoetis during the third quarter valued at about $278,000. Hedge funds and other institutional investors own 92.87% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: Trading Strategy Methods for Individual Investors

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Leave a Reply

Your email address will not be published. Required fields are marked *